Lauren Pitt
Head of Preclinical Development MyrioTx
Dr. Lauren Pitt is Head of Preclinical Development at MyrioTx, with nearly a decade of biotechnology experience spanning target identification, validation, and antibody‑based therapeutic development. She completed her PhD in Immunology at the University of Melbourne and conducted postdoctoral research at NYU School of Medicine. Dr. Pitt previously served as Director of R&D at Immunome.
Seminars
Tuesday 23rd June 2026
Synchronizing Global Regulatory Strategies by Navigating Non-Clinical Discrepancies to Expedite Global Approval of Next-Generation TCEs
2:00 pm
Join this workshop to navigate the shifting regulatory landscape for non-clinical safety, where the focus moves from traditional animal-heavy packages to a weight of evidence framework.
- Discussing policy inconsistencies across health authorities regarding animal usage, focussing on non-human primate studies
- Exploring ‘weight of evidence’ approaches for well-established or characterized targets to potentially waive or refine studies
- Debating scientific examples such as the necessity of repeated NHP studies for new generations of B-cell depleting CD3 T-cell engagers
- Uncovering the possibility of referencing marketed products for weight of evidence studies
- Advancing the idea of a ‘bridging study’ via in vitro comparative data rather than a full GLP NHP study when a new molecule only has slightly modified Fc regions
Wednesday 24th June 2026
Panel Discussion: Breaking the Efficacy Ceiling with Strategies to Enhance Depth & Durability in Next- Generation T-Cell Engagers
2:30 pm
- Analyzing recent clinical readouts to understand why safety optimized molecules often encounter an efficacy plateau and identifying the biological drivers behind limited therapeutic depth
- Evaluating the integration of signal 2 to overcome the efficacy ceiling, moving from transient T-cell activation to sustained, robust anti-tumor responses
- Utilizing advanced biomarker strategies to identify patientspecific T-cell characterises and TME features that predict which individuals will achieve durable remissions
Tuesday 23rd June 2026
Harnessing Precision Synapse Engineering by Designing Condition Specific Co- Stimulation to Advance Therapeutic Windows
8:30 am
Join this workshop to navigate the engineering trade-offs required to unlock the potential of costimulatory engagers in solid tumors.
- Discussing criteria for the selection of high value targets that require conditional activation to protect healthy tissue
- Analyzing the pros and cons of masking the TAA binder versus the CD3 binder
- Identifying the most robust protease-cleavable linkers and stable building blocks
- Discussing models to stimulate the human TME protease levels
- Strategies for evaluating the PK of post-cleaved active product vs pro-drug masked state
- Defining minimum preclinical data set required to justify the complexity of a conditional molecule over a regular one
